JP2020502179A - クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー - Google Patents

クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー Download PDF

Info

Publication number
JP2020502179A
JP2020502179A JP2019532806A JP2019532806A JP2020502179A JP 2020502179 A JP2020502179 A JP 2020502179A JP 2019532806 A JP2019532806 A JP 2019532806A JP 2019532806 A JP2019532806 A JP 2019532806A JP 2020502179 A JP2020502179 A JP 2020502179A
Authority
JP
Japan
Prior art keywords
allele
hla
tcdb
snp
drb1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019532806A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502179A5 (https=
Inventor
ショー，ピーター・エム
メロトラ，ディヴァン・ブイ
ブランチャード，レベッカ・エル
シェン，ジュドン
モグ，ロビン
ドア，メアリー・ベス
リー，ジュンファ
シー，シュン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2016/109900 external-priority patent/WO2018107388A1/en
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2020502179A publication Critical patent/JP2020502179A/ja
Publication of JP2020502179A5 publication Critical patent/JP2020502179A5/ja
Priority to JP2022212848A priority Critical patent/JP2023055222A/ja
Priority to JP2025002966A priority patent/JP2025061120A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2019532806A 2016-12-14 2017-12-07 クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー Pending JP2020502179A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022212848A JP2023055222A (ja) 2016-12-14 2022-12-29 クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー
JP2025002966A JP2025061120A (ja) 2016-12-14 2025-01-08 クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/109900 2016-12-14
PCT/CN2016/109900 WO2018107388A1 (en) 2016-12-14 2016-12-14 Human genetic markers associated with response to treatments that target clostridium difficile toxin b
US201762508066P 2017-05-18 2017-05-18
US62/508,066 2017-05-18
PCT/US2017/064985 WO2018111662A1 (en) 2016-12-14 2017-12-07 Human genetic markers associated with response to treatments that target clostridium difficile toxin b

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022212848A Division JP2023055222A (ja) 2016-12-14 2022-12-29 クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー

Publications (2)

Publication Number Publication Date
JP2020502179A true JP2020502179A (ja) 2020-01-23
JP2020502179A5 JP2020502179A5 (https=) 2021-02-04

Family

ID=62559092

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019532806A Pending JP2020502179A (ja) 2016-12-14 2017-12-07 クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー
JP2022212848A Pending JP2023055222A (ja) 2016-12-14 2022-12-29 クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー
JP2025002966A Ceased JP2025061120A (ja) 2016-12-14 2025-01-08 クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022212848A Pending JP2023055222A (ja) 2016-12-14 2022-12-29 クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー
JP2025002966A Ceased JP2025061120A (ja) 2016-12-14 2025-01-08 クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー

Country Status (9)

Country Link
US (1) US12071666B2 (https=)
EP (1) EP3555303B1 (https=)
JP (3) JP2020502179A (https=)
CN (1) CN110088300A (https=)
AU (1) AU2017375590A1 (https=)
BR (1) BR112019012203A2 (https=)
MX (1) MX2019007012A (https=)
RU (1) RU2761249C2 (https=)
WO (1) WO2018111662A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12071666B2 (en) * 2016-12-14 2024-08-27 Merck Sharp & Dohme Llc Human genetic markers associated with response to treatments that target clostridium difficile toxin B
CN112481395B (zh) * 2019-09-12 2024-10-18 深圳华大生命科学研究院 艰难梭菌耐药/低敏感进化分支snp标记及菌株类别鉴定方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502433A (ja) * 2009-08-21 2013-01-24 スミスクライン ビーチャム （コーク） リミテッド 癌を治療する方法
US20150344940A1 (en) * 2013-01-11 2015-12-03 Baylor College Of Medicine Biomarkers of recurrent clostridium difficile infection

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA2044591C (en) 1989-02-13 2002-08-13 James Langham Dale Detection of a nucleic acid sequence or a change therein
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5302509A (en) 1989-08-14 1994-04-12 Beckman Instruments, Inc. Method for sequencing polynucleotides
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
ATE198358T1 (de) 1992-04-27 2001-01-15 Dartmouth College Detektion von gensequenzen in biologischen flüssigkeiten
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
IL108159A (en) 1993-12-23 1998-02-08 Orgenics Ltd Apparatus for separation, concentration and detection of target molecules in liquid sample
EP0754240B1 (en) 1994-02-07 2003-08-20 Beckman Coulter, Inc. Ligase/polymerase-mediated genetic bit analysis of single nucleotide polymorphisms and its use in genetic analysis
US6300063B1 (en) 1995-11-29 2001-10-09 Affymetrix, Inc. Polymorphism detection
AU710425B2 (en) 1995-12-18 1999-09-23 Washington University Method for nucleic acid analysis using fluorescence resonance energy transfer
ES2215241T3 (es) 1996-11-06 2004-10-01 Sequenom, Inc. Procedimiento de espectrometria de masa.
DE19782097T1 (de) 1996-11-06 1999-10-14 Sequenom Inc Zusammensetzungen und Verfahren zur Immobilisierung von Nucleinsäuren an feste Träger
JP2010522560A (ja) * 2007-03-27 2010-07-08 デューク ユニバーシティ Ｈｉｖ疾患制限に関連する遺伝的変異体
US20100035265A1 (en) 2008-07-18 2010-02-11 Aris Floratos Biomarkers for Drug-Induced Liver Injury
WO2010050829A1 (en) 2008-10-31 2010-05-06 Vialactia Biosciences (Nz) Limited Marker assisted selection of a mammalian subject for desired immunoglobulin phenotype
PE20120056A1 (es) 2009-02-24 2012-02-05 Merck Sharp & Dohme Derivados de indol como antagonistas del receptor crth2
SG10201701055WA (en) * 2011-09-16 2017-03-30 Ucb Pharma Sa Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
AU2012328524B2 (en) * 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
EP3004386B1 (en) * 2013-05-29 2019-08-07 Immunexpress Pty Ltd Microbial markers and uses therefor
US9181632B1 (en) * 2013-09-09 2015-11-10 Merck Sharp & Dohme Corp. C.difficile toxin B CROP domain peptides, antibodies and complexes thereof
CN103665141B (zh) * 2013-12-31 2015-09-16 北京大学 与艰难梭菌细胞毒素b相互作用的蛋白
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
US12071666B2 (en) * 2016-12-14 2024-08-27 Merck Sharp & Dohme Llc Human genetic markers associated with response to treatments that target clostridium difficile toxin B
WO2018107388A1 (en) 2016-12-14 2018-06-21 Merck Sharp & Dohme Corp. Human genetic markers associated with response to treatments that target clostridium difficile toxin b

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502433A (ja) * 2009-08-21 2013-01-24 スミスクライン ビーチャム （コーク） リミテッド 癌を治療する方法
US20150344940A1 (en) * 2013-01-11 2015-12-03 Baylor College Of Medicine Biomarkers of recurrent clostridium difficile infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANTIMICROB.AGENTS CHEMOTHER., vol. 60, JPN6021047651, November 2016 (2016-11-01), pages 6471 - 6482, ISSN: 0005049373 *

Also Published As

Publication number Publication date
EP3555303A4 (en) 2020-06-24
AU2017375590A1 (en) 2019-06-13
CN110088300A (zh) 2019-08-02
MX2019007012A (es) 2019-11-28
RU2019122099A3 (https=) 2021-04-16
JP2025061120A (ja) 2025-04-10
RU2019122099A (ru) 2021-01-15
JP2023055222A (ja) 2023-04-17
US20200017909A1 (en) 2020-01-16
WO2018111662A1 (en) 2018-06-21
EP3555303B1 (en) 2022-12-21
US12071666B2 (en) 2024-08-27
BR112019012203A2 (pt) 2019-11-12
RU2761249C2 (ru) 2021-12-06
EP3555303A1 (en) 2019-10-23

Similar Documents

Publication Publication Date Title
US20210095345A1 (en) Method of identifying disease risk factors
EP3149487B1 (en) Improved therapeutic regimen for hypertension
EA020795B1 (ru) Генетические маркеры, ассоциированные с ответом на интерферон-альфа
JP2025061120A (ja) クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー
US20130274133A1 (en) Genetic variations in the interleukin-6 receptor gene as predictors of the response of patients to treatment with interleukin-6 receptor inhibitors
US20220177982A1 (en) Methods Of Identifying Subjects Having An Increased Risk Of Developing A Coronavirus Infection And Treatment Thereof
CA3163367A1 (en) Biomarkers and uses thereof in the treatment of chronic hepatitis b infection
US20210348235A1 (en) Genetic markers associated with response to crth2 receptor antagonists
WO2018107388A1 (en) Human genetic markers associated with response to treatments that target clostridium difficile toxin b
US20060177860A1 (en) Genetic markers in the HLA-DQBI gene associated with an adverse hematological response to drugs
AU2006213677A1 (en) Genetic markers in the CSF2RB gene associated with an adverse hematological response to drugs
WO2025246530A1 (en) Personalized anti-emetic treatment for chemotherapy-induced nausea and vomiting
Hasan et al. Alternative genome sequencing approaches of SARS-CoV-2 using Ion AmpliSeq Technology
JP6876988B2 (ja) メチシリン耐性黄色ブドウ球菌（ＭＲＳＡ）のｃｎａ遺伝子の一塩基多型を利用したＭＲＳＡの血流感染のリスクを予測する方法
Levy et al. PALISI PICFLU Investigators and Randolph AG (2019) Evaluation of Mannose Binding Lectin Gene Variants in Pediatric Influenza Virus-Related Critical Illness
Kanitwittaya et al. Genome-wide SNP-based linkage analysis of tuberculosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220531

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221229

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20221229

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221229

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230117

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230403

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230404

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250206